[
  {
    "ts": "2026-02-28T07:21:55+00:00",
    "headline": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
    "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
    "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "b3a432f2-b494-3238-bb8d-517294d25ae0",
      "content": {
        "id": "b3a432f2-b494-3238-bb8d-517294d25ae0",
        "contentType": "STORY",
        "title": "Here’s What Analysts Are Saying About CRISPR Therapeutics AG (CRSP)",
        "description": "",
        "summary": "CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, Morgan Stanley lifted the price target on CRISPR Therapeutics AG (NASDAQ:CRSP) to $33 from $32 and maintained an Underweight rating on the shares. The firm stated that it refreshed its estimates on the stock […]",
        "pubDate": "2026-02-28T07:21:55Z",
        "displayTime": "2026-02-28T07:21:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9emoTAGM5k9_AAOAzY4N1w--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yzCQgik8395vyxH4EhUh.w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/df05f4c88c5770e2c0eea2425efc8c06.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-crispr-therapeutics-ag-072155477.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T07:21:47+00:00",
    "headline": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
    "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
    "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "07e59b45-6ca3-3a20-939e-de3830aef9b1",
      "content": {
        "id": "07e59b45-6ca3-3a20-939e-de3830aef9b1",
        "contentType": "STORY",
        "title": "Here’s What Analysts Are Saying About Vertex Pharmaceuticals (VRTX)",
        "description": "",
        "summary": "Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the top gene therapy stocks to buy according to hedge funds. Canaccord lifted the price target on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to $441 from $411 on February 17 and maintained a Hold rating on the shares, telling investors that it updated its model after the fiscal Q4 results […]",
        "pubDate": "2026-02-28T07:21:47Z",
        "displayTime": "2026-02-28T07:21:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Is Vertex Pharmaceuticals Incorporated (VRTX) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l0DSaAhjgYrGYMIp84u.Dg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MOpM93.qarjxsgAhhmtxCQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/1072f698caaab685c17bd7da04c05995.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/analysts-saying-vertex-pharmaceuticals-vrtx-072147623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T13:09:44+00:00",
    "headline": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]",
    "url": "https://finance.yahoo.com/news/sana-biotechnology-inc-sana-bull-130944518.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "8aded8ab-6863-3f64-97c4-7a129c04ee31",
      "content": {
        "id": "8aded8ab-6863-3f64-97c4-7a129c04ee31",
        "contentType": "STORY",
        "title": "Sana Biotechnology, Inc. (SANA): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Sana Biotechnology, Inc. on Stock Invader’s Substack. In this article, we will summarize the bulls’ thesis on SANA. Sana Biotechnology, Inc.’s share was trading at $4.00 as of February 9th. Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. SANA has emerged as a […]",
        "pubDate": "2026-02-28T13:09:44Z",
        "displayTime": "2026-02-28T13:09:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Why Impact Biomedical Inc. (IBO) Surged On Thursday?",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fIdT9.k205RuBbbwuNwv4w--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1CFt_BfS6SqlkTGuw5_Dyw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/87c52b6250133265982f3f09a85b29c6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sana-biotechnology-inc-sana-bull-130944518.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sana-biotechnology-inc-sana-bull-130944518.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "SANA"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T15:07:58+00:00",
    "headline": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
    "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "f7aae562-f1b0-3e64-9e28-736140b8b990",
      "content": {
        "id": "f7aae562-f1b0-3e64-9e28-736140b8b990",
        "contentType": "STORY",
        "title": "Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory",
        "description": "",
        "summary": "We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $12.48 as of February 18th. Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. NTLA represents a potentially transformative opportunity in the biotechnology space, anchored by its pioneering work in […]",
        "pubDate": "2026-02-28T15:07:58Z",
        "displayTime": "2026-02-28T15:07:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891",
          "originalWidth": 750,
          "originalHeight": 577,
          "caption": "Best Innovative Stocks To Buy Now",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ld07zqdlyBnAgKzAtaE8vA--~B/aD01Nzc7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891.cf.webp",
              "width": 750,
              "height": 577,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kIENH8kRe3pdbdiMu1V.ag--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c730540d8a416c573a5dcfe934b0891.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-bull-150758771.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NTLA"
            },
            {
              "symbol": "REGN"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-28T19:07:12+00:00",
    "headline": "A Look At Vertex Pharmaceuticals (VRTX) Valuation As Shares Trade Near Vestra Fair Value Estimate",
    "summary": "Vertex Pharmaceuticals stock: context for recent performance Vertex Pharmaceuticals (VRTX) has attracted attention recently as investors weigh its current share price of $496.83 against company fundamentals, including annual revenue of US$12.0b and net income of US$3.95b. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been positive, with a 1-day share price return of 3.48% and a 90-day share price return of 14.58%. The 5-year total shareholder return of 134.38% points...",
    "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-vrtx-valuation-190712065.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "0f01ff9b-ac35-339c-8053-8f356d89c6b6",
      "content": {
        "id": "0f01ff9b-ac35-339c-8053-8f356d89c6b6",
        "contentType": "STORY",
        "title": "A Look At Vertex Pharmaceuticals (VRTX) Valuation As Shares Trade Near Vestra Fair Value Estimate",
        "description": "",
        "summary": "Vertex Pharmaceuticals stock: context for recent performance Vertex Pharmaceuticals (VRTX) has attracted attention recently as investors weigh its current share price of $496.83 against company fundamentals, including annual revenue of US$12.0b and net income of US$3.95b. See our latest analysis for Vertex Pharmaceuticals. Recent trading has been positive, with a 1-day share price return of 3.48% and a 90-day share price return of 14.58%. The 5-year total shareholder return of 134.38% points...",
        "pubDate": "2026-02-28T19:07:12Z",
        "displayTime": "2026-02-28T19:07:12Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-vrtx-valuation-190712065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/look-vertex-pharmaceuticals-vrtx-valuation-190712065.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]